Breast Cancer
Conditions
Brief summary
The purpose of this study is to examine the impact of a lifestyle intervention. The study will examine the Stay on Track program, dietary and activity patterns, body composition, biomarkers and quality of life in breast cancer patients undergoing radiation therapy.
Detailed description
Research Design. The investigators will be conducting an randomized trial in 60 women undergoing radiation treatment for breast cancer to examine the feasibility of a 12-week lifestyle intervention that addresses diet and physical activity and to explore the impact on behavioral, biological and psychosocial outcomes. Procedure Summary. Patients who are eligible are consented by the research coordinator, after which a baseline assessment will be scheduled. The baseline assessment requires 60 minutes and includes questionnaires, height/weight, dual energy x-ray absorptiometry (DEXA), and phlebotomy. Participants will also wear the Fitbit for one week to establish baseline activity level. After the baseline assessment, women are then randomly assigned to: the 12-week Stay on Track lifestyle intervention or the 12-week self-guided control. Both groups complete a post-intervention and a 3-month follow-up visit identical to their baseline assessment. Self-guided controls can utilize their Fitbit and will receive informative binders 24 weeks' post-intervention.
Interventions
The intervention examines dietary and activity patterns, body composition, biomarkers and quality of life in breast cancer patients undergoing radiation therapy
Sponsors
Study design
Eligibility
Inclusion criteria
1. \> 18 years of age; 2. confirmed primary non-metastatic breast adenocarcinoma; 3. planned lumpectomy/segmentectomy/partial mastectomy surgery for primary breast cancer; 4. planning to undergo adjuvant whole breast radiation therapy following a lumpectomy; 5. Have a Karnovsky Performance Score of 70 or above (see Appendix) 6. Patient's Body Mass Index (BMI) is greater than determine by the treating physician, not currently meeting physical activity guidelines: moderate physical activity for at least 30 minutes at least five days a week AND 2 weekly sessions of resistance exercise; 7. have access to a mobile phone with capacity for text messaging (either unlimited or aware and accepting of text messaging charges); 8. understand and speak English; 9. physically able to engage in the intervention; 10. accepting of randomization (Note that anti-estrogen therapy is allowed.)
Exclusion criteria
1. Patients who have metastatic disease; 2. Patients with a history of prior malignancy within the past 3 years, other than non-melanoma skin cancer. 3. Patients with serious orthopedic, cardiovascular, or pulmonary conditions, have serious psychiatric or cognitive problems. 4. Patients who have received chemotherapy for their breast cancer. 5. Patients with prior radiotherapy to primary site or adjacent site that results in overlapping radiation fields.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Percent time of personal fitness tracker use during the intervention period for the Stay on Track intervention arm | 6 months |
Secondary
| Measure | Time frame |
|---|---|
| The percent of eligible patient who choose to take part in the study | 6 months |
| Number of personal exercise sessions were attended by members in the Stay on Track Intervention Arm | 6 months |
| Changes in lean soft tissue over the study period associated with intervention and activity | 6 months |
| Changes in BMI (weight and height will be combined to report BMI in kg/m^2) over the study period associated with intervention and activity | 6 months |
| Measures of physical activity (self-report and objective) | 6 months |
| Dietary intake (assessed via Full Length Block Questionnaire) | 6 months |
| Measures of fatigue (Piper Fatigue Scale Score and physician CTCAE v4.0 Scoring) | 6 months |
| Measures of skin side effects (CTCAE v4.0 Scoring) | 6 months |
| Quality of life (FACT-B Questionnaire) over the study period associated with intervention and activity | 6 months |
| Measures of pain (PROMIS Scale v1.0- Pain Intensity 3a Questionnaire) over the study period associated with intervention and activity | 6 months |
| Changes in biomarker (GM-CSF) associated with intervention and activity | 6 months |
| Changes in biomarker (IFN-gamma) associated with intervention and activity | 6 months |
| Changes in biomarker (IL-1alpha) associated with intervention and activity | 6 months |
| Percent of participant retention thoughout the 12-week intervention through the six month follow-up | 6 months |
| Changes in biomarker (IL-4) associated with intervention and activity | 6 months |
| Changes in biomarker (IL-6) associated with intervention and activity | 6 months |
| Changes in biomarker (IL-8) associated with intervention and activity | 6 months |
| Changes in biomarker (IL-10) associated with intervention and activity | 6 months |
| Changes in biomarker (IL-12) associated with intervention and activity | 6 months |
| Changes in biomarker (MCP-1) associated with intervention and activity | 6 months |
| Changes in biomarker (TNF-alpha) associated with intervention and activity | 6 months |
| Changes in biomarker (adiponectin) associated with intervention and activity | 6 months |
| Changes in biomarker (leptin) associated with intervention and activity | 6 months |
| Changes in biomarker (CRP) associated with intervention and activity | 6 months |
| Changes in blood insulin level associated with intervention and activity | 6 months |
| Changes in blood hemoglobin A1C level associated with intervention and activity | 6 months |
| Changes in blood glucose level associated with intervention and activity | 6 months |
| Changes in biomarker (IL-1beta) associated with intervention and activity | 6 months |
Countries
United States